Tags

Type your tag names separated by a space and hit enter

Ezetimibe: a novel option for lowering cholesterol.
Expert Rev Cardiovasc Ther 2003; 1(1):11-21ER

Abstract

Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease but lowering LDL-cholesterol to levels established in current National Cholesterol Education Program (NCEP) guidelines provides significant risk reduction. Nevertheless, many patients receiving lipid-lowering therapy, particularly those at highest coronary heart disease risk, do not reach LDL-cholesterol goals with their current medications. Ezetimibe (Zetia, Merck Schering-Plough) is the first of a new class of lipid-lowering drugs known as cholesterol absorption inhibitors. Ezetimibe has a favorable pharmacokinetic profile, which allows it to be administered once daily and to be given in conjunction with statins. In a series of randomized, controlled, multicenter studies, ezetimibe produced significant improvements in levels of LDL-cholesterol and other lipid parameters when used as monotherapy, with a safety profile comparable with that of placebo. Furthermore, coadministration of ezetimibe with a statin (simvastatin, atorvastatin, lovastatin, or pravastatin) was more effective than statin monotherapy in lowering LDL-cholesterol and improving other lipid parameters. Moreover, coadministration of ezetimibe with a statin allowed a greater percentage of patients to achieve treatment goals established in NCEP guidelines. The safety and side-effect profile of ezetimibe plus statin coadministration therapy was generally comparable with that of statin monotherapy. These studies establish ezetimibe as an effective lipid-lowering agent, which will likely be useful in the management of a broad range of patients with hypercholesterolemia. Ezetimibe can be used in conjunction with a statin at the beginning of therapy, or it can be added if patients do not achieve their LDL-cholesterol goal with statins alone.

Authors+Show Affiliations

Chicago Center for Clinical Research, IL 60610-4324, USA. mdavidson@protocare.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15030293

Citation

Davidson, Michael H.. "Ezetimibe: a Novel Option for Lowering Cholesterol." Expert Review of Cardiovascular Therapy, vol. 1, no. 1, 2003, pp. 11-21.
Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003;1(1):11-21.
Davidson, M. H. (2003). Ezetimibe: a novel option for lowering cholesterol. Expert Review of Cardiovascular Therapy, 1(1), pp. 11-21.
Davidson MH. Ezetimibe: a Novel Option for Lowering Cholesterol. Expert Rev Cardiovasc Ther. 2003;1(1):11-21. PubMed PMID: 15030293.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ezetimibe: a novel option for lowering cholesterol. A1 - Davidson,Michael H, PY - 2004/3/20/pubmed PY - 2004/5/8/medline PY - 2004/3/20/entrez SP - 11 EP - 21 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 1 IS - 1 N2 - Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease but lowering LDL-cholesterol to levels established in current National Cholesterol Education Program (NCEP) guidelines provides significant risk reduction. Nevertheless, many patients receiving lipid-lowering therapy, particularly those at highest coronary heart disease risk, do not reach LDL-cholesterol goals with their current medications. Ezetimibe (Zetia, Merck Schering-Plough) is the first of a new class of lipid-lowering drugs known as cholesterol absorption inhibitors. Ezetimibe has a favorable pharmacokinetic profile, which allows it to be administered once daily and to be given in conjunction with statins. In a series of randomized, controlled, multicenter studies, ezetimibe produced significant improvements in levels of LDL-cholesterol and other lipid parameters when used as monotherapy, with a safety profile comparable with that of placebo. Furthermore, coadministration of ezetimibe with a statin (simvastatin, atorvastatin, lovastatin, or pravastatin) was more effective than statin monotherapy in lowering LDL-cholesterol and improving other lipid parameters. Moreover, coadministration of ezetimibe with a statin allowed a greater percentage of patients to achieve treatment goals established in NCEP guidelines. The safety and side-effect profile of ezetimibe plus statin coadministration therapy was generally comparable with that of statin monotherapy. These studies establish ezetimibe as an effective lipid-lowering agent, which will likely be useful in the management of a broad range of patients with hypercholesterolemia. Ezetimibe can be used in conjunction with a statin at the beginning of therapy, or it can be added if patients do not achieve their LDL-cholesterol goal with statins alone. SN - 1477-9072 UR - https://www.unboundmedicine.com/medline/citation/15030293/Ezetimibe:_a_novel_option_for_lowering_cholesterol_ L2 - http://www.tandfonline.com/doi/full/10.1586/14779072.1.1.11 DB - PRIME DP - Unbound Medicine ER -